Artiva Biotherapeutics, Inc. (ARTV) research
Artiva Biotherapeutics, Inc.- Sector
- Healthcare
- Industry
- Biotechnology
- Last price
- $8.61
- As of
Artiva Biotherapeutics, Inc. (ARTV): 4 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-09-11.
As of . Source: SEC EDGAR filings for ARTV. Method and limitations.
Share the ARTV intelligence card
See ARTV live in the terminal
Track ARTV's insider trades, 13F flows, options positioning, and cross asset confluence as they update, on one live board. Free account.
Open the live ARTV terminal, freeActive signals for ARTV
- highCONSENSUS_BUY
3 tracked funds increased ARTV this 2026Q2, institutional consensus
- highCONSENSUS_BUY
3 tracked funds increased ARTV this 2026Q2, institutional consensus
- mediumNEW_POSITION
VIKING GLOBAL INVESTORS LP new position in ARTV
- highINSTITUTIONAL_SURGE
RENAISSANCE TECHNOLOGIES LLC added +89% to ARTV (2026Q2)
- highINSTITUTIONAL_SURGE
CITADEL ADVISORS LLC added +379% to ARTV (2026Q2)
FREE, NO ACCOUNT
Every signal on ARTV, as it fires
You are seeing 5 of 17 signals recorded on ARTV since 2026-06-21.
The five above landed across 2 days. The other 12 were recorded on 2 other days. 11 of the 17 are institutional flow rows, which arrive in batches on filing days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in ARTV (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| VIKING GLOBAL INVESTORS LPCUSIP 04317A107 · 2026Q2 | $25.3M | 0.07% | , |
| CITADEL ADVISORS LLCCUSIP 04317A107 · 2026Q2 | $5.9M | 0.00% | , |
| RENAISSANCE TECHNOLOGIES LLCCUSIP 04317A107 · 2026Q2 | $1.5M | 0.00% | , |
| TWO SIGMA INVESTMENTS, LPCUSIP 04317A107 · 2026Q2 | $762K | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, ARTV
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-KSEC EDGAR ↗
ARTV against its peers
ARTV's return on equity of -76.3% ranks in the 50th percentile of 20 Biotechnology sub-industry peers, fiscal periods ending between 2025-12-31 and 2026-06-30.
| Metric | ARTV | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 0.0 USD | 14.2M USD | 7 | 13 |
| Operating margin | n/a | -357.7% | n/a | 12 |
| Net margin | n/a | -372.2% | n/a | 12 |
| Return on equity | -76.3% | -74.3% | 50 | 20 |
Peers (23): ARCT, FENC, CCCC, TTRX, ZURA, EDIT, IRD, CABA, GALT, RLMD, PRTA, LRMR, PROK, INDP, PRLD, BNTC, EVMN, BBOT, MYGN, RCKT, DMAC, OBIO, OCGN. Left out: PRTC (period gap), RZLT (no annual filing). Fiscal periods ending between 2025-12-31 and 2026-06-30. Every figure is one full fiscal year read from one annual filing (ARTV: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
See more ARTV signals as they fire
Kresmion publishes filings, 13F flows, on-chain whale activity, and cross-asset signals in real time. Open a live board scoped to ARTVand get the insider, 13F, options, and confluence read in one view.